Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

Go back to Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

Ultragenyx Pharma (RARE) PT Raised to $80 at Wedbush

August 6, 2018 7:50 AM EDT

Wedbush raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $80.00 (from $71.00) while maintaining a Outperform rating.

... More